BDBM591393 Synthesis of (2S)-2-(1-{1-[(2E)-4-(dimethylamino)but-2-enoyl]azetidin-3-yl}-N-methylformamido)-N-[(8S,14S)-22-ethyl-4-hydroxy-21-[2-(methoxymethyl)pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-16-oxa-10,22,28-triazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),2,4,6(29),20,23::US11566007, Example A71

SMILES CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)C1CN(C1)C(=O)\C=C\CN(C)C)-c1cccnc1COC

InChI Key InChIKey=AHEVKKOSRJOUOY-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 591393   

TargetGTPase KRas [G13C](Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 55nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGTPase KRas [G12V](Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 5.50E+3nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGTPase KRas [G12S](Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 5.50E+3nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGTPase KRas(Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 5.50E+3nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGTPase KRas [G12D](Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 5.50E+3nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGTPase KRas [G12C](Human)
Revolution Medicines

US Patent
LigandPNGBDBM591393(US11566007, Example A71 | Synthesis of (2S)-2-(1-{...)
Affinity DataIC50: 55nMAssay Description:A variety of Ras proteins may be inhibited by compounds of the present invention (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof at positions 12, 13 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent